172 related articles for article (PubMed ID: 32172800)
1. Targeted Alpha-Particle Therapy for Hematologic Malignancies.
Jurcic JG
Semin Nucl Med; 2020 Mar; 50(2):152-161. PubMed ID: 32172800
[TBL] [Abstract][Full Text] [Related]
2. Targeted Alpha-Particle Therapy for Hematologic Malignancies.
Jurcic JG
J Med Imaging Radiat Sci; 2019 Dec; 50(4 Suppl 1):S53-S57. PubMed ID: 31253514
[TBL] [Abstract][Full Text] [Related]
3. Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies.
Jurcic JG
Curr Radiopharm; 2018; 11(3):192-199. PubMed ID: 29793418
[TBL] [Abstract][Full Text] [Related]
4. Targeted alpha-particle immunotherapy for acute myeloid leukemia.
Jurcic JG; Rosenblat TL
Am Soc Clin Oncol Educ Book; 2014; ():e126-31. PubMed ID: 24857092
[TBL] [Abstract][Full Text] [Related]
5. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia.
Rosenblat TL; McDevitt MR; Mulford DA; Pandit-Taskar N; Divgi CR; Panageas KS; Heaney ML; Chanel S; Morgenstern A; Sgouros G; Larson SM; Scheinberg DA; Jurcic JG
Clin Cancer Res; 2010 Nov; 16(21):5303-11. PubMed ID: 20858843
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab.
Rosenblat TL; McDevitt MR; Carrasquillo JA; Pandit-Taskar N; Frattini MG; Maslak PG; Park JH; Douer D; Cicic D; Larson SM; Scheinberg DA; Jurcic JG
Clin Cancer Res; 2022 May; 28(10):2030-2037. PubMed ID: 35247915
[TBL] [Abstract][Full Text] [Related]
7. Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma.
Bell MM; Gutsche NT; King AP; Baidoo KE; Kelada OJ; Choyke PL; Escorcia FE
Molecules; 2020 Dec; 26(1):. PubMed ID: 33374953
[TBL] [Abstract][Full Text] [Related]
8. Where do we stand with radioimmunotherapy for acute myeloid leukemia?
Walter RB
Expert Opin Biol Ther; 2022 May; 22(5):555-561. PubMed ID: 35350938
[TBL] [Abstract][Full Text] [Related]
9. Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.
Hagemann UB; Wickstroem K; Hammer S; Bjerke RM; Zitzmann-Kolbe S; Ryan OB; Karlsson J; Scholz A; Hennekes H; Mumberg D; Cuthbertson AS
Cancer Biother Radiopharm; 2020 Sep; 35(7):497-510. PubMed ID: 32255671
[TBL] [Abstract][Full Text] [Related]
10. Targeted alpha particle immunotherapy for myeloid leukemia.
Jurcic JG; Larson SM; Sgouros G; McDevitt MR; Finn RD; Divgi CR; Ballangrud AM; Hamacher KA; Ma D; Humm JL; Brechbiel MW; Molinet R; Scheinberg DA
Blood; 2002 Aug; 100(4):1233-9. PubMed ID: 12149203
[TBL] [Abstract][Full Text] [Related]
11. Targeted Alpha Therapy: Current Clinical Applications.
Guerra Liberal FDC; O'Sullivan JM; McMahon SJ; Prise KM
Cancer Biother Radiopharm; 2020 Aug; 35(6):404-417. PubMed ID: 32552031
[TBL] [Abstract][Full Text] [Related]
12. Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications.
Miederer M; Scheinberg DA; McDevitt MR
Adv Drug Deliv Rev; 2008 Sep; 60(12):1371-82. PubMed ID: 18514364
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.
Miederer M; McDevitt MR; Sgouros G; Kramer K; Cheung NK; Scheinberg DA
J Nucl Med; 2004 Jan; 45(1):129-37. PubMed ID: 14734685
[TBL] [Abstract][Full Text] [Related]
14. Targeted alpha therapy with bismuth-213 and actinium-225: Meeting future demand.
Bruchertseifer F; Kellerbauer A; Malmbeck R; Morgenstern A
J Labelled Comp Radiopharm; 2019 Sep; 62(11):794-802. PubMed ID: 31369165
[TBL] [Abstract][Full Text] [Related]
15. Targeted alpha therapy: part I.
Elgqvist J
Curr Radiopharm; 2011 Jul; 4(3):176. PubMed ID: 22201706
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy of human tumours.
Larson SM; Carrasquillo JA; Cheung NK; Press OW
Nat Rev Cancer; 2015 Jun; 15(6):347-60. PubMed ID: 25998714
[TBL] [Abstract][Full Text] [Related]
17. Alpha radioimmunotherapy using
Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
[TBL] [Abstract][Full Text] [Related]
18. Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.
Lee D; Li M; Bednarz B; Schultz MK
Radiat Res; 2018 Sep; 190(3):236-247. PubMed ID: 29944461
[TBL] [Abstract][Full Text] [Related]
19. Targeted Alpha Therapy with Thorium-227.
Frantellizzi V; Cosma L; Brunotti G; Pani A; Spanu A; Nuvoli S; De Cristofaro F; Civitelli L; De Vincentis G
Cancer Biother Radiopharm; 2020 Aug; 35(6):437-445. PubMed ID: 31967907
[TBL] [Abstract][Full Text] [Related]
20. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.
Ballangrud AM; Yang WH; Palm S; Enmon R; Borchardt PE; Pellegrini VA; McDevitt MR; Scheinberg DA; Sgouros G
Clin Cancer Res; 2004 Jul; 10(13):4489-97. PubMed ID: 15240541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
